Systematic review with meta-analysis: the effects of family history on the risk of Barrett's oesophagus and oesophageal adenocarcinoma.

Tytuł:: Systematic review with meta-analysis: the effects of family history on the risk of Barrett's oesophagus and oesophageal adenocarcinoma.
Autorzy:: Peters Y; Department of Gastroenterology and Hepatology, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
van Grinsven E; Department of Gastroenterology and Hepatology, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Siersema PD; Department of Gastroenterology and Hepatology, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Oct; Vol. 54 (7), pp. 868-879. Date of Electronic Publication: 2021 Aug 12.
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-
MeSH Terms:: Adenocarcinoma*/diagnosis
Adenocarcinoma*/epidemiology
Adenocarcinoma*/genetics
Barrett Esophagus*/diagnosis
Barrett Esophagus*/epidemiology
Barrett Esophagus*/genetics
Esophageal Neoplasms*/diagnosis
Esophageal Neoplasms*/epidemiology
Esophageal Neoplasms*/genetics
Early Diagnosis ; Humans ; Risk Factors
References:: Am J Gastroenterol. 1999 May;94(5):1172-8. (PMID: 10235188)
Clin Gastroenterol Hepatol. 2019 Apr;17(5):869-877.e5. (PMID: 30213587)
Am J Gastroenterol. 2018 Dec;113(12):1819-1827. (PMID: 29867176)
Nat Rev Dis Primers. 2017 Jul 27;3:17048. (PMID: 28748917)
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2657-2667.e9. (PMID: 31525516)
J Med Genet. 2003 Sep;40(9):651-6. (PMID: 12960209)
JAMA. 2000 Apr 19;283(15):2008-12. (PMID: 10789670)
Scand J Gastroenterol. 2005 Sep;40(9):1127-8. (PMID: 16211720)
J Clin Oncol. 2015 Nov 1;33(31):3660-7. (PMID: 26324357)
Am J Gastroenterol. 2002 May;97(5):1127-32. (PMID: 12017151)
Science. 2018 Nov 23;362(6417):911-917. (PMID: 30337457)
Gastroenterology. 1992 Apr;102(4 Pt 1):1400-2. (PMID: 1551547)
Cancer. 2016 Sep 1;122(17):2633-45. (PMID: 27258162)
Am J Gastroenterol. 2004 Nov;99(11):2107-14. (PMID: 15554988)
JAMA. 1986 Jul 4;256(1):51-4. (PMID: 3712713)
J Natl Cancer Inst. 2013 Nov 20;105(22):1711-8. (PMID: 24168968)
J Clin Gastroenterol. 2011 Nov-Dec;45(10):867-71. (PMID: 21617543)
Clin Gastroenterol Hepatol. 2006 Jul;4(7):840-5. (PMID: 16678496)
Dig Dis Sci. 2011 Jun;56(6):1702-6. (PMID: 21347561)
Clin Transl Gastroenterol. 2020 Apr;11(4):e00151. (PMID: 32251017)
Gut. 2020 Jul;69(7):1169-1172. (PMID: 32098798)
Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. (PMID: 31439127)
Am J Gastroenterol. 2015 Jan;110(1):148-58. (PMID: 25488897)
Int J Cancer. 2001 Jul 1;93(1):148-52. (PMID: 11391635)
Gastroenterology. 2011 Mar;140(3):1084-91. (PMID: 21376940)
Gastrointest Endosc. 2019 Nov;90(5):707-717.e1. (PMID: 31152737)
Arab J Gastroenterol. 2013 Jun;14(2):51-4. (PMID: 23820500)
Clin Gastroenterol Hepatol. 2014 Oct;12(10):1656-63.e1. (PMID: 24480679)
Am J Gastroenterol. 2017 Aug;112(8):1247-1255. (PMID: 28585555)
Res Synth Methods. 2021 Jan;12(1):55-61. (PMID: 32336025)
Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51. (PMID: 26526079)
Gastroenterology. 1997 Nov;113(5):1449-56. (PMID: 9352846)
Clin Res Hepatol Gastroenterol. 2011 Dec;35(12):831-8. (PMID: 21924696)
Gut. 2002 Sep;51(3):323-8. (PMID: 12171951)
Gut. 2003 Aug;52(8):1085-9. (PMID: 12865263)
Lancet. 2020 Aug 1;396(10247):333-344. (PMID: 32738955)
Dig Dis Sci. 2019 Dec;64(12):3463-3470. (PMID: 31273597)
Am J Epidemiol. 1982 Sep;116(3):547-53. (PMID: 7124721)
Gastrointest Endosc. 2012 Oct;76(4):707-18. (PMID: 22985638)
Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):376-83. (PMID: 22178570)
Endoscopy. 2017 Feb;49(2):191-198. (PMID: 28122386)
Gut. 2014 Jan;63(1):7-42. (PMID: 24165758)
Dis Esophagus. 2007;20(1):53-7. (PMID: 17227311)
Am J Epidemiol. 1995 May 1;141(9):863-71. (PMID: 7717363)
Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):666-74. (PMID: 20200424)
BMC Cancer. 2014 Feb 04;14:60. (PMID: 24495377)
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1668-73. (PMID: 16985029)
Clin Epidemiol. 2018 Sep 04;10:1169-1179. (PMID: 30233251)
Eur J Cancer. 2018 May;94:138-147. (PMID: 29571082)
Gastroenterology. 2003 Dec;125(6):1670-7. (PMID: 14724819)
Ann Intern Med. 2013 Feb 19;158(4):280-6. (PMID: 23420236)
Epidemiology. 1995 Sep;6(5):511-9. (PMID: 8562628)
Gastroenterology. 2005 Dec;129(6):1825-31. (PMID: 16344051)
N Engl J Med. 2011 Oct 13;365(15):1375-83. (PMID: 21995385)
United European Gastroenterol J. 2019 Mar;7(2):225-229. (PMID: 31080607)
Lancet Oncol. 2016 Oct;17(10):1363-1373. (PMID: 27527254)
Gut. 2020 Sep;69(9):1564-1571. (PMID: 32606208)
Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):757-60. (PMID: 10919748)
Aliment Pharmacol Ther. 2020 Jul;52(1):20-36. (PMID: 32452599)
Gastroenterology. 2018 Dec;155(6):1720-1728.e4. (PMID: 30165050)
Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571)
Aliment Pharmacol Ther. 2021 Oct;54(7):868-879. (PMID: 34383966)
Nat Rev Dis Primers. 2019 May 23;5(1):35. (PMID: 31123267)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
Entry Date(s):: Date Created: 20210812 Date Completed: 20210916 Latest Revision: 20220731
Update Code:: 20240105
PubMed Central ID:: PMC9292032
DOI:: 10.1111/apt.16558
PMID:: 34383966
: Czasopismo naukowe

Pełny tekst

Background: Current guidelines recommend different screening approaches for individuals with a family history of Barrett's oesophagus (BO) or oesophageal adenocarcinoma (OAC), varying from no screening to screening all individuals with a positive family history.
Aims: To determine evidence-based risk estimates for individuals with a family history of BO or OAC METHODS: We systematically searched Pubmed, Embase and Cochrane Library until October 2020 to identify all studies that reported on the association between family history and the risk of BO and OAC. Pooled summary estimates of adjusted relative risks and prevalence of familial BO/OAC with 95% confidence intervals (CIs) were calculated using a random effects model.
Results: Fourteen studies comprising 16 189 BO/OAC patients were analysed. Familial clustering was seen in 8.84% (95% CI: 5.54-13.82) and 4.37% (95% CI: 2.15-8.69) of patients with BO and OAC, respectively (nine studies). Screening first-degree relatives of BO patients had a diagnostic yield between 12% and 44% for BO (four studies). However, the yield for high-grade dysplasia and OAC was low (<2%). Individuals with a positive family history had a higher risk of having BO (aRR 3.26; 95% CI 1.43-7.40; I 2 = 46%; three studies) and OAC (aRR 2.19; 95% CI 1.14-4.21; I 2 = 48%; five studies) compared to individuals without a family history.
Conclusions: A verified family history of BO or OAC is a strong risk factor for both BO and OAC. A positive family history could be a clinically meaningful way to identify high-risk individuals who may benefit from early detection strategies.
(© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja